Levetiracetam* (Levetiracetam) — Medicare Part D spending
Multiple manufacturers (45) · Rank #268 by total Part D spend · CMS data year 2023
Medicare Part D spent $171,482,383 on Levetiracetam* (Levetiracetam) in 2023, the #268 drug by total Part D spending out of 3,598 drugs. That worked out to about $0.33 per dosage unit, $39 per claim and $224 per beneficiary, across 4,449,740 claims for 766,583 beneficiaries. Average spending per dosage unit fell -4.5% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Levetiracetam* (Levetiracetam) spending at a glance (2023)
| Metric | Levetiracetam* (Levetiracetam) |
|---|---|
| Total Part D spending (2023) | $171,482,383 |
| Total spending (2022) | $174,363,884 |
| Year-over-year change in total spending | -1.7% |
| Average spending per dosage unit (2023) | $0.33 |
| Change in spend per dosage unit (YoY) | -4.5% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +3.7% |
| Average spending per claim (2023) | $39 |
| Average spending per beneficiary (2023) | $224 |
| Total claims (2023) | 4,449,740 |
| Beneficiaries (2023) | 766,583 |
| Total dosage units (2023) | 628,122,579 |
| Manufacturer(s) | Multiple manufacturers (45) |
| National rank by total spend (of 3,598 drugs) | #268 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $174,363,884 | $171,482,383 | -1.7% |
| Avg spend per dosage unit | $0.35 | $0.33 | -4.5% |
| Avg spend per claim | $40 | $39 | — |
| Avg spend per beneficiary | $235 | $224 | — |
| Total claims | 4,319,900 | 4,449,740 | — |
| Beneficiaries | 740,432 | 766,583 | — |
How Levetiracetam* compares with nearby drugs
Drugs with total Part D spending closest to Levetiracetam* (Levetiracetam):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Levetiracetam* (Levetiracetam) (this drug, #268) | $171,482,383 | $0.33 | -4.5% |
| Esomeprazole Magnesium (#266) | $172,016,821 | $0.96 | -29.8% |
| Escitalopram Oxalate (#267) | $171,914,954 | $0.25 | -3.2% |
| Xywav (Sodium,Calcium,Mag,Pot Oxybate) (#269) | $168,733,996 | $34.48 | +6.0% |
| Cabenuva (Cabotegravir/Rilpivirine) (#270) | $165,605,768 | $1,140.51 | +4.4% |
| Prednisolone Acetate (#271) | $163,897,057 | $6.24 | -6.3% |
Frequently asked questions
How much does Medicare Part D spend on Levetiracetam*?
Medicare Part D spent $171,482,383 on Levetiracetam* (Levetiracetam) in 2023 (the latest CMS data year), across 4,449,740 claims for 766,583 beneficiaries. That ranks #268 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Levetiracetam*?
In 2023, the weighted average Medicare Part D spending per dosage unit for Levetiracetam* (Levetiracetam) was $0.33. Compared with 2022 it fell -4.5%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Levetiracetam*?
CMS attributes Levetiracetam* (Levetiracetam) to Multiple manufacturers (45) in the 2023 Part D spending file. Average spending per claim was $39 and per beneficiary $224.
Is the Levetiracetam* figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20